City and District Leaders Visit Peak Spring Festival
Release time:
2020-07-22
12 , on the first day of work in the Spring Festival, Zhang Xuhui, secretary of the Party Trade Union of Jinhua Economic and Technological Development Zone, visited Jianfeng Group to pay New Year's greetings and had discussions with Chairman Jiang Xiaomeng, General Manager Yu Jianhong, Chairman Yan Xijun and President Wu Nai Feng of Tianshili Holding Group. Secretary Zhang Xuhui introduced to Yan Xijun and his party the layout of the development zone's big health industry, the investment promotion cooperation plan with domestic health industry companies and other related information, and warmly invited Tianshili to Jinhua to develop the big health industry.
13 , Zhao Guorong, secretary of the party Committee and director of Jinhua Municipal Market Supervision and Administration Bureau, and his party visited Jianfeng and had discussions with Jiang Xiaomeng, chairman of the group company, Huang Jinlong, deputy general manager and general manager of the pharmaceutical company, and Xiang Chongping, deputy general manager. Chairman Jiang Xiaomeng introduced the basic situation of the group in terms of business structure, development planning, production and operation, scientific research capabilities, and project construction. The two sides also exchanged views on the supervision of special drug distribution, the upgrading of the drug control platform and industrial development.
13 morning, Lu Saihua, deputy director of Jinhua Municipal Market Supervision Bureau, and his party visited the municipal pharmaceutical company and held discussions with Wu Weisheng, general manager of the pharmaceutical company, Li Anhua, deputy general manager, and Jiang Xiaohua, quality director. Deputy Director Lu Saihua inquired in detail about the operation of pharmaceutical companies, the difficulties in the operation process, and the opinions of enterprises in the "three services" activities advocated by the municipal government. The two sides also exchanged views on the distribution qualifications of pharmaceutical companies in GSP certification, refined hemp poison release and other special drugs in 2019
4 7 " city belt bidding and procurement policy, and the delay in the arrival of paper first camp data of upstream manufacturers after the two-vote system. Lu Saihua asked pharmaceutical companies to adapt to the new situation, adjust their business ideas, explore new business strategies, strengthen internal management, tap potential and open up markets. At the same time, it is necessary to conscientiously implement the quality management standards for drug management, actively investigate and rectify hidden risk points, and continue to operate in compliance. (Ni Yingzhen, Fan Tufa)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page